Persistence and Long-Term Disease Control of Interleukin-17 Inhibitors and Interleukin-23 Inhibitors in Patients with Psoriasis: A Nationwide Cohort Study in Japan
IL-23i was associated with longer persistence and a longer post-discontinuation treatment-free period than IL-17i in patients with psoriasis. These findings may provide actionable insights for healthcare providers and patients as they develop treatment strategies. Future research integrating comprehensive clinical data is warranted to evaluate different treatment strategies, thereby informing clinical decision-making.
Authors
- Bryan Wahking (ORCID: https://orcid.org/0000-0001-6016-8209)
- Chia-Ling Chang
- Tong Li
- Junya Masuda
- Yongjing Zhang
- Hong Qiu
- Shinichi Imafuku
- Grace Hui-Min Wu
- Youran Xu
Institutions
- Johnson & Johnson (United States) (US)
- Fukuoka University (JP)
- Johnson & Johnson (Singapore) (SG)
- Johnson & Johnson (Brazil) (BR)
Publication Details
- Journal
- Psoriasis Targets and Therapy
- Published
- 2026-02-01
- DOI
- https://doi.org/10.2147/ptt.s565823
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00